Last reviewed · How we verify
levofloxacin-based sequential therapy
Levofloxacin-based sequential therapy uses a fluoroquinolone antibiotic in a multi-step treatment regimen to eradicate bacterial infections, particularly Helicobacter pylori in peptic ulcer disease.
Levofloxacin-based sequential therapy uses a fluoroquinolone antibiotic in a multi-step treatment regimen to eradicate bacterial infections, particularly Helicobacter pylori in peptic ulcer disease. Used for Helicobacter pylori eradication in peptic ulcer disease (as part of sequential therapy regimen).
At a glance
| Generic name | levofloxacin-based sequential therapy |
|---|---|
| Also known as | Takepron, Cravit, Flagyl, Amoxicillin |
| Sponsor | National Taiwan University Hospital |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase; topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease; Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Levofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. In sequential therapy protocols, levofloxacin is administered in a defined sequence with other antimicrobial agents (typically proton pump inhibitors and other antibiotics) to improve eradication rates of H. pylori and reduce antibiotic resistance compared to standard triple or dual therapy.
Approved indications
- Helicobacter pylori eradication in peptic ulcer disease (as part of sequential therapy regimen)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Headache
- Dizziness
- Tendinopathy
- QT prolongation
Key clinical trials
- Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection (PHASE4)
- Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication (NA)
- Levofloxacin Concomitant Versus Levofloxacin Sequential (PHASE4)
- Eradication of H. Pylori Infection With Moxifloxacin (PHASE3)
- Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP (PHASE3)
- Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori (PHASE4)
- Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients (PHASE4)
- Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |